A carregar...
Cost-Effectiveness of IL28B Genotype-Guided Protease Inhibitor Triple Therapy versus Standard of Care Treatment in Patients with Hepatitis C Genotypes 2 or 3 Infection
BACKGROUND & AIMS: Triple therapy (adding protease inhibitors to standard of care (SOC)) dramatically increases treatment response in selected patients with Hepatitis C Virus (HCV). Interleukin 28B (IL28B) genotyping helps predict responsiveness in these patients; however, the economic implicati...
Na minha lista:
| Publicado no: | Public Health Genomics |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4275401/ https://ncbi.nlm.nih.gov/pubmed/25247313 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000365939 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|